These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

835 related items for PubMed ID: 17430246

  • 21. Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease.
    Sagare AP, Bell RD, Zlokovic BV.
    J Alzheimers Dis; 2013; 33 Suppl 1(0 1):S87-100. PubMed ID: 22751174
    [Abstract] [Full Text] [Related]

  • 22. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.
    Deane R, Sagare A, Zlokovic BV.
    Curr Pharm Des; 2008; 14(16):1601-5. PubMed ID: 18673201
    [Abstract] [Full Text] [Related]

  • 23. Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis.
    Jeynes B, Provias J.
    Curr Alzheimer Res; 2008 Oct; 5(5):432-7. PubMed ID: 18855584
    [Abstract] [Full Text] [Related]

  • 24. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.
    Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV.
    Mol Neurodegener; 2018 Oct 19; 13(1):57. PubMed ID: 30340601
    [Abstract] [Full Text] [Related]

  • 25. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
    Lue LF, Yan SD, Stern DM, Walker DG.
    Curr Drug Targets CNS Neurol Disord; 2005 Jun 19; 4(3):249-66. PubMed ID: 15975028
    [Abstract] [Full Text] [Related]

  • 26. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain.
    Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA.
    J Neurochem; 2010 Dec 19; 115(5):1077-89. PubMed ID: 20854368
    [Abstract] [Full Text] [Related]

  • 27. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease.
    Hartz AM, Miller DS, Bauer B.
    Mol Pharmacol; 2010 May 19; 77(5):715-23. PubMed ID: 20101004
    [Abstract] [Full Text] [Related]

  • 28. Endothelial LRP1 - A Potential Target for the Treatment of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.
    Storck SE, Pietrzik CU.
    Pharm Res; 2017 Dec 19; 34(12):2637-2651. PubMed ID: 28948494
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice.
    Abdallah IM, Al-Shami KM, Yang E, Kaddoumi A.
    Int J Mol Sci; 2021 Jan 27; 22(3):. PubMed ID: 33513818
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Aβ1-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-κB signaling.
    Park R, Kook SY, Park JC, Mook-Jung I.
    Cell Death Dis; 2014 Jun 26; 5(6):e1299. PubMed ID: 24967961
    [Abstract] [Full Text] [Related]

  • 34. Aβ₁₋₄₂-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca²⁺-calcineurin signaling.
    Kook SY, Hong HS, Moon M, Ha CM, Chang S, Mook-Jung I.
    J Neurosci; 2012 Jun 27; 32(26):8845-54. PubMed ID: 22745485
    [Abstract] [Full Text] [Related]

  • 35. Chronic cerebral hypoperfusion-induced impairment of Aβ clearance requires HB-EGF-dependent sequential activation of HIF1α and MMP9.
    Ashok A, Rai NK, Raza W, Pandey R, Bandyopadhyay S.
    Neurobiol Dis; 2016 Nov 27; 95():179-93. PubMed ID: 27431094
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease.
    Jaeger LB, Dohgu S, Sultana R, Lynch JL, Owen JB, Erickson MA, Shah GN, Price TO, Fleegal-Demotta MA, Butterfield DA, Banks WA.
    Brain Behav Immun; 2009 May 27; 23(4):507-17. PubMed ID: 19486646
    [Abstract] [Full Text] [Related]

  • 39. Local perfusion of capillaries reveals disrupted beta-amyloid homeostasis at the blood-brain barrier in Tg2576 murine Alzheimer's model.
    Hanafy AS, Lamprecht A, Dietrich D.
    Fluids Barriers CNS; 2023 Nov 22; 20(1):85. PubMed ID: 37993886
    [Abstract] [Full Text] [Related]

  • 40. Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease.
    Leclerc E, Sturchler E, Vetter SW, Heizmann CW.
    Rev Neurosci; 2009 Nov 22; 20(2):95-110. PubMed ID: 19774788
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.